Edgewise Therapeutics reports continued successful drug trials, $17.4M loss in third quarter November 3, 2022 3:15:15 pm
Edgewise Therapeutics receives FDA approval for muscular dystrophy drug trials, launches stock offering September 13, 2022 3:38:02 pm
Edgewise reports positive interim results from Becker muscular dystrophy treatment trial June 20, 2022 1:02:49 pm
Edgewise Therapeutics shows positive results from muscular dystrophy drug trials January 6, 2022 10:16:10 pm
